

**ASX Announcement | 13 November 2023**  
**Visioneering Technologies, Inc. (ASX:VTI)**

## **Completion of Rights Offering**

**Visioneering Technologies, Inc. (ASX: VTI)** ('**Visioneering**' or 'the **Company**'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, advises that it has completed its 5 for 9 non-renounceable pro rata non-renounceable rights offering announced to ASX on 10 October 2023 (**Rights Offering**). The Rights Offering closed at 5:00pm (Sydney time) on 6 November 2023.

The Company has today issued 10,777,095 CHESS Depository Interests (**CDIs**) under the Rights Offering at \$0.22 per CDI, raising A\$2,370,960.90 before costs. In total, 9,690,206 entitlements were accepted by eligible securityholders and 1,086,889 additional CDIs were applied for under the Top-Up Facility, representing approximately 61% of the Rights Offering.

The Company's largest CDI holder, Thorney Investment Group, took up its pro rata entitlement under the Rights Offering.

**Dr. Juan Carlos Aragón, CEO of Visioneering, commented,** "We greatly appreciate the support of Thorney Investment Group, our largest CDI holder, and many of our current investors for participating in this capital raise. I joined Visioneering in early October hopeful that the impending announcement of the PROTECT Clinical Trial results would be favorable. As we announced on October 12<sup>th</sup> at the American Academy of Optometry meeting in New Orleans, the preliminary one-year results were very positive, as they were consistent with those of the only treatment approved by the U.S. Food and Drug Administration (FDA) for myopia progression control. These results have driven increased interest from Eye Care Practitioners and potential strategic partners across the globe. I'm very excited about the opportunities that lie ahead for the Company and hope to reward our investors for continuing to invest in the future of the Visioneering."

6,844,016 CDIs (representing 6,844,016 shares of Class A Common Stock) were not taken up under the Rights Offering by eligible securityholders (**Shortfall Securities**). As stated in the Offer Booklet for the Rights Offering, the Company will seek to place the Shortfall Securities. The Company has to date received commitments from existing securityholders and new investors to subscribe for an aggregate of approximately 1,605,000 Shortfall Securities (to raise a total of approximately A\$353,000 at A\$0.22 per Shortfall Security). The Company is expecting to finalise these subscriptions and issue the relevant Shortfall Securities in early December 2023. It is the Company's intention to place additional Shortfall Securities in due course but in any case by 6 February 2024 (being within 3 months after the closing date of 6 November 2023). Please refer to the Offer Booklet for further details on the issue of the shortfall.

The Company advises that the placement to the non-executive Directors and the conversion of the outstanding convertible notes have also been completed.

**Ends**

**This release was authorized by the CEO, Dr. Juan Carlos Aragón.**

For more information, please contact:

<b>Company</b>	<b>Investor and media relations</b>
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: <a href="mailto:blane@vtivision.com">blane@vtivision.com</a>	Haley Chartres H^CK Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

### About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit [www.vtivision.com](http://www.vtivision.com) or call +1 844-884-5367, ext. 104.

### Foreign ownership restrictions

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.